Clinicians increasingly evaluate neurodegenerative disorders through the lens of multicellular biological dysfunction. Recent clinical research underscores the critical role of the neurovascular unit, which integrates neurons, glial cells, and cerebral vasculature. Consequently, evaluating plasma biomarkers in Alzheimer's provides invaluable insights into pathology progression. In this context, researchers analyzed large-scale data from the Alzheimer's Disease Neuroimaging Initiative. Ultimately, the findings reveal that astrocytic, microglial, and endothelial markers follow distinct, asynchronous biological trajectories across clinical stages.

Multicellular Pathology and the ADNI Cohort Analysis

Historically, clinicians defined Alzheimer's disease solely through amyloid accumulation and tau neurofibrillary tangles. However, contemporary neurobiology recognizes that neurovascular unit breakdown drives substantial cognitive decline. Astrocytes and microglia modulate local inflammation, while endothelial cells maintain blood-brain barrier integrity. Therefore, assessing circulating proteins released by these distinct cells allows non-invasive monitoring of brain health.

To evaluate these mechanisms, investigators conducted a retrospective cohort analysis utilizing Alzheimer's Disease Neuroimaging Initiative data. The study evaluated 2,650 participants classified into cognitively unimpaired, mild cognitive impairment, and dementia cohorts. Furthermore, researchers quantified astrocytic glial fibrillary acidic protein and microglial soluble triggering receptor expressed on myeloid cells 2. Additionally, they evaluated vascular endothelial growth factor, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1. Statistical models systematically adjusted for baseline age, sex, education, and APOE epsilon 4 status. Moreover, vascular analyses fully controlled for blood pressure, body mass index, cardiovascular medications, smoking, and renal function. This rigorous methodology successfully minimized systemic confounding factors.

Diagnostic Performance of Plasma Biomarkers in Alzheimer's

Baseline evaluations revealed striking differences between astrocytic activation and microglial or vascular changes. Glial fibrillary acidic protein exhibited a robust, stepwise elevation across disease stages. Specifically, dementia patients demonstrated 56.3% higher plasma concentrations than cognitively unimpaired individuals. In addition, this astrocytic marker achieved an impressive area under the receiver operating characteristic curve of 0.82. Such discrimination confirms its exceptional diagnostic value in identifying active neuroinflammation.

In contrast, soluble triggering receptor expressed on myeloid cells 2 failed to separate clinical groups. Its plasma distributions showed substantial overlap among cognitively normal adults, impaired participants, and dementia patients. Meanwhile, vascular biomarkers demonstrated statistically significant, yet modest, baseline elevations. Dementia patients exhibited 14.1% higher vascular endothelial growth factor and 14.7% higher soluble vascular cell adhesion molecule-1. However, both vascular markers displayed poor discriminative curves of only 0.61 and 0.63. Furthermore, more than 80% of individual values overlapped across cohorts. Consequently, baseline vascular markers lack clinical utility for diagnosing individual patients.

Longitudinal Trajectories of Astrocytic and Microglial Activation

Tracking biological progression over time provides essential prognostic data for clinicians managing cognitive decline. In this cohort, linear mixed-effects models uncovered distinct annual trajectory patterns among unimpaired participants. Glial fibrillary acidic protein increased at an annual rate of 4.50% among cognitively normal older adults. Similarly, soluble triggering receptor expressed on myeloid cells 2 rose by 2.99% annually in the same baseline cohort.

Interestingly, neither glial marker demonstrated a significant diagnosis-by-time interaction. This finding indicates that glial activation increases steadily with biological aging, independent of baseline clinical diagnosis. Therefore, astrocytic stress accumulates progressively even before noticeable cognitive symptoms appear. Moreover, this continuous upward drift suggests that reactive astrogliosis represents a persistent biological response throughout neurodegeneration. In clinical practice, physicians must account for these age-dependent shifts when interpreting blood tests. Longitudinal tracking of astrocytic proteins may thereby assist clinicians in identifying accelerated biological aging. Nevertheless, microglial markers remain uninformative for longitudinal disease staging.

Vascular Biomarker Dynamics and Neurovascular Uncoupling

Endothelial markers demonstrated unexpected, complex temporal patterns over 12 months of longitudinal observation. In cognitively unimpaired individuals, soluble intercellular adhesion molecule-1 concentrations declined over one year. However, this physiological decline was noticeably attenuated in participants with mild cognitive impairment and dementia. Conversely, soluble vascular cell adhesion molecule-1 increased over 12 months in unimpaired adults but showed negative diagnosis-by-time interactions in impaired individuals.

Importantly, these vascular trajectories remained completely unaltered after extensive covariate adjustments. Controlling for cardiometabolic parameters, including blood pressure, body mass index, and antihypertensive therapy, did not modify the results. Additionally, adjusting for renal filtration rates and smoking history yielded identical outcomes. Even when researchers distinguished stable impairment from progressive dementia converters, the vascular patterns persisted. Correlations among vascular markers were consistently strong and well estimated. In contrast, correlations between glial and vascular markers were statistically non-significant. Thus, glial activation and endothelial disruption progress asynchronously rather than through synchronized biological cascades.

Clinical Implications and Future Diagnostic Directions

These empirical insights provide critical guidance for physicians integrating blood-based biomarkers into clinical workflows. Currently, geriatricians, neurologists, and general physicians face growing demand for early dementia diagnostics. Plasma glial fibrillary acidic protein emerges as a highly reliable peripheral marker of neurodegenerative disease pathology. Because it displays substantial group-level divergence and excellent discrimination, it significantly enhances diagnostic confidence during initial cognitive assessments.

However, clinicians must not interpret vascular biomarker elevations as definitive evidence of Alzheimer's disease. Although endothelial proteins rise significantly in dementia cohorts, their extreme distribution overlap prevents reliable individual diagnosis. Therefore, ordering vascular adhesion panels will not resolve diagnostic dilemmas for individual patients. Instead, clinicians should interpret vascular elevations as general indicators of broader systemic and cerebrovascular stress. Furthermore, physicians must manage coexisting cardiovascular risks through blood pressure optimization, glycemic control, and lifestyle interventions. Ultimately, unraveling the dialogue between glial cells, neurons, and cerebral blood vessels will catalyze more precise diagnostic testing and individualized dementia therapy.

Frequently Asked Questions

Why is plasma GFAP superior to vascular markers for diagnosing Alzheimer's disease?

Plasma glial fibrillary acidic protein demonstrates exceptional diagnostic accuracy because it reflects reactive astrogliosis directly linked to central amyloid pathology. In clinical studies, it achieves an area under the curve of 0.82, displaying marked separation between diagnostic groups. Conversely, vascular markers exhibit extensive distribution overlap exceeding 80% among patients. Consequently, while vascular proteins indicate general endothelial dysfunction, they lack the diagnostic sensitivity and specificity necessary to identify individual dementia cases accurately.

Do cardiovascular comorbidities affect the interpretation of vascular biomarkers in dementia?

Cardiovascular risk factors certainly influence peripheral endothelial health, yet rigorous analyses show that primary diagnostic associations persist after adjusting for these confounders. Adjusting for systolic blood pressure, body mass index, smoking history, antihypertensive therapy, and kidney filtration does not eliminate cohort-level biomarker differences. Nevertheless, because high individual variability persists across all patient subsets, clinicians should evaluate vascular markers to assess systemic cardiometabolic vulnerability rather than using them to diagnose Alzheimer's pathology.

How should clinicians integrate plasma glial biomarkers into routine cognitive evaluations?

Clinicians should utilize plasma glial biomarkers as supportive tools alongside standard neuropsychological assessments, clinical history, and structural neuroimaging. Elevated astrocytic proteins strongly suggest active neuroinflammation and underlying neurodegeneration, prompting timely specialist referral or advanced biomarker testing. However, physicians must remember that normal microglial markers do not rule out pathology. Therefore, combining validated blood biomarkers with comprehensive clinical evaluation ensures the most accurate diagnosis and prevents premature or inappropriate therapeutic conclusions.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Jahanbin K et al. Glial and Vascular Plasma Biomarkers Across the Alzheimer's Disease Continuum: An ADNI-Based Longitudinal Study. FASEB Bioadv. 2026 Sep undefined. doi: 10.1096/fba.2026-00194. PMID: 42763575.
2. Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505-3516. doi: 10.1093/brain/awab223.
3. Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022;18(12):2669-2686. doi: 10.1002/alz.12756.